Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.

Antiviral research - 1 Dec 2015

Ramadhany Ririn, Hirai Itaru, Sasaki Tadahiro, Ono Ken-ichiro, Ramasoota Pongrama, Ikuta Kazuyoshi, Kurosu Takeshi

Abstract excerpt

Antibody-dependent enhancement (ADE) of dengue virus (DENV) infectivity is thought to play a crucial role in severe dengue disease. It occurs when pre-existing sub-neutralizing anti-DENV antibody (Ab) produced from a primary infection encounters a DENV serotype different from that of the initial infection and forms immune complexes, which enable the efficient infection of Fcγ receptor-bearing cells. However, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Cross Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dengue

Share to Dengue Virus

Share to K562 Cells

Share to Receptors, IgG

Share to Severe Dengue

Share to Vero Cells

Source

Identifiers

PMID: 26522769
DOI: 10.1016/j.antiviral.2015.10.012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.PMID 26522769Read ↗

Generation and therapeutic efficacy of the novel Fc-modified cross-neutralizing human monoclonal antibodies against dengue virusSemantic proximity Read ↗

Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.Semantic proximity Read ↗

An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with <i>in vivo</i> therapeutic potencySemantic proximity Read ↗

COVID-19 Vaccination Induces Cross-Reactive Dengue Antibodies with Altered Isotype Profiles and In Vitro ADESemantic proximity Read ↗

Structure-guided affinity maturation of a single-chain variable fragment antibody against the Fu-bc epitope of the dengue virus envelope proteinSemantic proximity Read ↗

Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.Semantic proximity Read ↗

Immunopathogenesis of dengue haemorrhagic feverSemantic proximity Read ↗

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.Semantic proximity Read ↗

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.Semantic proximity Read ↗

The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.Semantic proximity Read ↗

Mechanistic Study of Broadly Neutralizing Human Monoclonal Antibodies against Dengue Virus That Target the Fusion LoopSemantic proximity Read ↗

A human <i>ex vivo</i> dengue virus neutralization assay identifies priority antibodies and epitopes for vaccines and therapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.